logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Dostarlimab in addition to carboplatin and paclitaxel for recurrent or primary advanced endometrial cancer

< Back

Dostarlimab in addition to carboplatin and paclitaxel for recurrent or primary advanced endometrial cancer

Drugs

Cancer and Palliative Care

May 2021


Dostarlimab in addition to carboplatin and paclitaxel is in developmentfor recurrent or primary advanced endometrial cancer. Endometrial (uterine) cancer is cancer of the lining of the womb. Recurrent cancer is cancer that has come back after treatment. Advanced cancer is cancer that cannot normally be cured or controlled. Endometrial cancer is characterised by abnormal vaginal bleeding (after the menopause, between periods) and can also cause symptoms such as pain during sex and lower abdominal (tummy) pain. Typically, advanced endometrial cancer is treated by using a combination of surgery, radiotherapy and/or chemotherapy. Dostarlimab is a type of immunotherapy (therapy that targets the immune system) that is administered intravenously (IV) and targets a receptor (protein) for PD-1. Blockage of PD-1 allows for the body’s own immune cells (called T-cells) to attack and kill the cancer cells. If licensed, dostarlimab – in addition to carboplatin and paclitaxel – would offer an additional treatment option for patients with recurrent or primary advanced endometrial cancer.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts